What Impact Biomedical does

Impact BioMedical Inc. is a publicly traded biotechnology and consumer wellness company (NYSE American: IBO), headquartered in Houston, Texas, that develops and patents science-based platforms targeting inflammatory disease, oncology, neurology, metabolic disorders, infectious disease, and indoor air quality. The company was spun out of DSS Inc. through an IPO in September 2024 and operates four core technology platforms: Linebacker (small-molecule X-bonded polyphenols designed to down-regulate PIM kinase for solid tumor cancers and inflammatory/neurological disorders), Laetose (a patented low-glycemic sugar composition with myo-inositol that inhibits TNF-alpha, covered by US Patent #11,898,184), Equivir (an FDA GRAS-eligible polyphenol blend with antiviral effects intended for OTC respiratory infection applications), and 3F (a botanical terpene-based formulation with insect repellent and antimicrobial properties). In February 2025 the company expanded into air purification via the acquisition of Celios, contributing its first reported revenue and adding design, system, and method patents with exclusivity through 2043.

The business model is built on a capital-efficient, asset-light architecture in which Impact BioMedical retains ownership of its 69 issued and 60+ pending worldwide patents and monetizes them primarily through licensing, co-development, and royalty arrangements rather than internal clinical and commercial build-out. Strategic partners include ProPhase Labs (NASDAQ: PRPH) for Equivir and Linebacker development and commercialization, Chemia Corp for 3F manufacturing, and Dr. Ashleys Limited (Hong Kong) for a proposed reverse merger transaction targeted to close by July 1, 2026, intended to create a larger combined NYSE American-listed entity with global pharmaceutical manufacturing capabilities. Direct revenue is currently limited to consumer e-commerce sales of Celios products through dsspureair.com, which generated $32,000 in FY2025.

The company faces material financial headwinds including a $11.87M FY2025 net loss (improved from $24.77M in FY2024), a going concern audit qualification from Grassi & Co., CPAs, P.C. filed in the 2025 10-K, an underwriter securities class action investigation by Rosen Law Firm, and CEO/CFO share sale activity in 2026. Customer base is concentrated among a small set of strategic licensing and development partners and one consumer e-commerce channel, with no disclosed enterprise customers or contracted revenue.

Name

Impact Biomedical

Legal name

Impact BioMedical Inc.

Website

https://impactbiomedinc.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Impact BioMedical Inc. is a Houston-based, NYSE American-listed (IBO) biotechnology and consumer wellness company that develops patented polyphenol, botanical, and air purification platforms (Linebacker, Laetose, 3F, Equivir, Celios) and monetizes them through licensing partnerships with ProPhase Labs and Chemia Corp and direct-to-consumer e-commerce.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals and Consumer Wellness

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Healthy Aging & Cognitive Support Supplements (CRADAGAM), Better-for-You / Functional Snacks (Low Sugar, Keto, Probiotic, Fortified) (CRADABAM)

Keywords

• Biopharmaceutical research
• Consumer health products
• Polyphenol drug platforms
• Air purification technology
• Intellectual property licensing

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Licensing and Royalty Revenue: Impact BioMedical licenses its proprietary technology platforms (Laetose, 3F, Linebacker, Equivir) to external partners. Laetose and 3F are described as 'proven and available for immediate partnering' with potential to generate both license milestone and royalty revenue in 2025 and beyond. ProPhase Labs is developing Equivir as an OTC health supplement, with potential milestone and royalty arrangements.
2. Product Revenue — Celios Air Purification: Revenue generated from the sale of Celios portable air purification products. Impact BioMedical acquired Celios in February 2025 in an all-equity transaction valued at approximately $1.15 million. First revenue from Celios ($32,000) was recorded in fiscal year 2025.
3. Partnership Milestone Payments: Co-development agreements with partners such as ProPhase Labs may generate upfront, development, regulatory, and commercial milestone payments. For example, Linebacker is under evaluation for oncology applications with pre-clinical studies ongoing, with results projected in 2025, advancing toward IND discussions and potential Phase 1 study initiation.
4. Merger and Strategic Transaction Value: Impact BioMedical is pursuing a reverse merger with Dr. Ashleys Limited to create a new publicly traded entity on NYSE American, targeting completion by July 1, 2026. The transaction includes a $15 million debt conversion with DSS Inc. through issuance of 31.9 million shares, designed to strengthen the financial position of the combined entity.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Impact BioMedical discovers, develops, patents, and commercializes proprietary biopharmaceutical and consumer wellness platforms through five core technologies: Linebacker (polyphenol oncology/anti-inflammatory pipeline), Laetose (low-glycemic sugar composition), Equivir (antiviral GRAS-eligible supplement), 3F (botanical insect repellent and antimicrobial), and Celios (portable air purification hardware). The company monetizes these primarily through licensing and co-development partnerships, with direct-to-consumer hardware sales via the Celios brand.

Product overview

Impact Biomedical is a pioneering biotechnology company that discovers, confirms, and patents unique science and technologies, transforming them into innovative human health and wellness solutions. The company operates a diversified portfolio organized across three segments: (1) Biopharmaceuticals including Linebacker™ for oncology, inflammatory disease, and neurology applications, and Laetose™ for metabolic/anti-inflammatory therapeutics; (2) Consumer Wellness including Equivir™ and Equivir-G™ (antiviral supplements), 3F™ (natural insect repellent and antimicrobial), and Laetose™ (dietary supplement); and (3) Air Purification through Celios®, acquired in February 2025 to expand the health and wellness portfolio. The company leverages strategic partnerships in licensing, co-development, and joint ventures to commercialize its proprietary technology platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Linebacker™ A biopharmaceutical platform employing small molecule X-bonded polyphenols (Linebacker-1 and Linebacker-2) designed to improve potency, efficacy, bioavailability, and permeability of therapeutics. Down-regulates PIM kinase for solid tumor treatment. Targeted at oncology (lung, colon), inflammatory, and neurological disorders; being co-developed with ProPhase Labs toward IND discussions and potential Phase 1 studies.
• Laetose™ Low-glycemic sugar composition combining multiple sugars independently paired with myo-inositol to inhibit the inflammatory and metabolic response of sugar alone. Reduces caloric intake and glycemic index while inhibiting TNF-alpha. Applications span food and beverage, dietary supplements, and therapeutics for diabetes and inflammatory disease.
• 3F™ (Functional Fragrance Formulation) Botanical formulation (e.g., terpenes) with demonstrated insect repellency and antimicrobial/antiviral effect. All-natural composition free of synthetic components, applicable to detergents, lotions, shampoos, fabrics, and antimicrobial coatings. Manufactured and developed in partnership with Chemia Corp.
• Equivir™ and Equivir-G™ Novel FDA GRAS-eligible polyphenol blend with proven antiviral effects, intended for OTC medication/supplement or Rx applications targeting upper respiratory infections. Equivir-G is a variant that adds gallic acid for an additional unique antiviral formulation. Developed in partnership with ProPhase Labs as an OTC health supplement.
• Celios® Air Purification Products Advanced portable air purification products delivering 'virtually clean room' air quality through patented US-manufactured filter technology. Design, system, and method patents issued in the US and other countries with exclusivity through 2043. Sold direct-to-consumer via the dsspureair.com e-commerce storefront.

Quantifiable outcome

• Linebacker down-regulates PIM kinase which plays a key role as an oncogene in solid tumor cancers (lung and colon)
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Dr. Ashleys LimitedcoreStrategic or Co-development Partner · 21 June 2025Dr. Ashleys Limited, a Hong Kong-based global pharmaceutical company, and Impact BioMedical executed a merger and share exchange agreement on June 21, 2025, for a strategic reverse merger transaction. Upon closing, Dr. Ashleys will acquire Impact BioMedical through a reverse merger resulting in a newly formed combined entity (PubCo) traded on NYSE American under the name 'Dr Ashleys Limited.' The transaction aims to leverage Impact BioMedical's patent portfolio and expand global reach. Target closing: July 1, 2026.
• Celios®supportingStrategic or Co-development Partner · 26 February 2025Impact BioMedical acquired Celios, a pioneering air purification technology company, in an all-equity transaction valued at approximately $1.15 million. Celios brings advanced air purification capability with design, system, and method patents issued in the US and other countries with exclusivity through 2043.
• ProPhase Labs (NASDAQ: PRPH)coreStrategic or Co-development PartnerProPhase Labs is a global development and commercialization partner for Equivir and Linebacker technologies. Equivir is under development with initial application planned as an OTC health supplement, with studies ongoing to support market claims. Linebacker is under evaluation with initial oncology targets (lung, colon) with pre-clinical studies ongoing and results projected for 2025, advancing toward IND discussions and Phase 1 study plans.
• Chemia CorpsupportingOEM/ Whitelabel/ Licensing PartnerChemia Corp, a global manufacturing and development partner based in St. Louis, MO, manufactures and develops 3F Functional Fragrance products. 3F is available for additional partnering and out-licensing. The partnership covers natural insect repellent and antimicrobial formulations.
• Sichenzia Ross Ference Carmel LLPsupportingOthersSichenzia Ross Ference Carmel LLP serves as US legal counsel to Impact BioMedical in connection with the proposed reverse merger with Dr. Ashleys Limited.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• ProPhase Labs: ProPhase Labs (NASDAQ: PRPH) is Impact BioMedical's primary development and commercialization partner for Equivir and Linebacker, and operates a comparable OTC supplement + diagnostics portfolio targeting consumer health channels. Its direct involvement in IBO's pipeline makes it the single most operationally comparable peer.
• Aytu BioPharma: Aytu BioPharma (NASDAQ: AYTU) is a small-cap specialty pharma with a diversified prescription and consumer health product portfolio, similar in scale and microcap public-company profile to Impact BioMedical, with overlapping reliance on licensing and out-licensing for pipeline value capture.
• Tonix Pharmaceuticals: Tonix Pharmaceuticals (NASDAQ: TNXP) is a small-cap clinical-stage specialty pharma with multiple platform assets across CNS, immunology, and infectious disease—an analogous multi-platform microcap biotech structure to Impact BioMedical's Linebacker/Equivir strategy.
• Citius Oncology: Citius Oncology (NASDAQ: CTOR) is a small specialty oncology pharmaceutical company targeting solid tumor and hematological cancers, directly comparable to Impact BioMedical's Linebacker oncology pipeline in scale, stage, and regulatory pathway.
• BioXcel Therapeutics: BioXcel Therapeutics (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company developing immunology and neuroscience therapies using AI-derived drug repurposing—a comparable microcap specialty pharma profile with multi-platform neurology/inflammation focus overlapping Linebacker's targets.
• Salarius Pharmaceuticals: Salarius Pharmaceuticals (NASDAQ: SLRX) is a microcap clinical-stage oncology company with pipeline assets targeting epigenetic and protein-degradation mechanisms in solid tumors—comparable scale and development stage to Impact BioMedical's Linebacker oncology program.

Broad incumbents

• DSS Inc. DSS Inc. (NYSE American: DSS) is Impact BioMedical's former parent and significant shareholder via the $15M debt conversion. DSS is a diversified conglomerate operating multiple subsidiaries in biotech, securities, and digital assets, providing the broader ecosystem context for IBO's spin-out and continuing capital relationship.

Emerging players

• InMed Pharmaceuticals: InMed Pharmaceuticals (NASDAQ: INM) is a small clinical-stage biotech developing plant-derived cannabinoid-like polyphenol therapies for neurological and dermatological conditions—comparable to Impact BioMedical's botanical polyphenol approach with Linebacker and Laetose, with similar early-stage commercialization risk.
• Helius Medical Technologies: Helius Medical Technologies is a small neurotech/medical device company where IBO COO Mark Suseck previously led global sales and marketing. It represents a peer-size and stage reference point for Impact BioMedical's pre-commercial specialty pharma/neurology positioning.
• Vivacitas Oncology: Vivacitas Oncology is a small private oncology company where IBO COO Mark Suseck previously served as CEO. It is a relevant emerging-player reference for Impact BioMedical's pipeline structure and operational approach to early-stage oncology development and licensing.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/impactbiomedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impact Biomedical